Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The erythromycin breath test for the prediction of drug clearance
Autore:
Rivory, LP; Slaviero, KA; Hoskins, JM; Clarke, SJ;
Indirizzi:
Sydney Canc Ctr, Camperdown, NSW 2050, Australia Sydney Canc Ctr Camperdown NSW Australia 2050 erdown, NSW 2050, Australia Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia Univ Sydney Sydney NSW Australia 2006 rmacol, Sydney, NSW 2006, Australia
Titolo Testata:
CLINICAL PHARMACOKINETICS
fascicolo: 3, volume: 40, anno: 2001,
pagine: 151 - 158
SICI:
0312-5963(2001)40:3<151:TEBTFT>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-VIVO; CYTOCHROME P4503A; CYP3A METABOLISM; PHARMACOKINETICS; LIVER; KETOCONAZOLE; VERAPAMIL; MIDAZOLAM;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Rivory, LP Sydney Canc Ctr, Missenden Rd, Camperdown, NSW 2050, Australia Sydney Canc Ctr Missenden Rd Camperdown NSW Australia 2050 alia
Citazione:
L.P. Rivory et al., "The erythromycin breath test for the prediction of drug clearance", CLIN PHARMA, 40(3), 2001, pp. 151-158

Abstract

The erythromycin breath test (EBT) is a putative probe of cytochrome P450 (CYP) 3A4 activity in vivo. Therefore, the EBT might prove useful for the individualisation of doses of drugs that have a low therapeutic window (for example the immunosuppressants or cytotoxics) and are metabolised by CYP3A4. However, there is a lack of consensus as to how the EBT should be used topredict total body clearance (CL), and the results so far have been largely disappointing. We argue that the required assumption that individuals produce 5 mmol of CO2/min per m(2) at rest is one of the problems with the existing EBT, as the literature suggests significant variability and possible gender differences in this parameter. An examination of the EBT with a simple compartment model suggests that alternative parameters could be mon useful in the prediction of CL. In particular, there is theoretical support for the use of the time-point at which breath radioactivity is maximal (t(max)) as a correlatefor CL. This is in agreement with our recent study of the pharmacokineticsof erythromycin in patients with cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 19:18:19